Profund Advisors LLC Has $420,000 Position in ICU Medical, Inc. (ICUI)
Profund Advisors LLC increased its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 18.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,436 shares of the medical instruments supplier’s stock after acquiring an additional 372 shares during the period. Profund Advisors LLC’s holdings in ICU Medical were worth $420,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. State Board of Administration of Florida Retirement System raised its position in ICU Medical by 1.9% during the first quarter. State Board of Administration of Florida Retirement System now owns 7,080 shares of the medical instruments supplier’s stock valued at $1,081,000 after purchasing an additional 130 shares in the last quarter. First Trust Advisors LP lifted its stake in ICU Medical by 42.0% during the first quarter. First Trust Advisors LP now owns 10,188 shares of the medical instruments supplier’s stock worth $1,556,000 after purchasing an additional 3,013 shares during the last quarter. Swiss National Bank lifted its stake in ICU Medical by 3.6% during the first quarter. Swiss National Bank now owns 25,619 shares of the medical instruments supplier’s stock worth $3,912,000 after purchasing an additional 900 shares during the last quarter. Karp Capital Management Corp bought a new stake in ICU Medical during the first quarter worth $1,046,000. Finally, Sei Investments Co. lifted its stake in ICU Medical by 8.5% during the first quarter. Sei Investments Co. now owns 14,244 shares of the medical instruments supplier’s stock worth $2,176,000 after purchasing an additional 1,114 shares during the last quarter. Institutional investors and hedge funds own 78.13% of the company’s stock.
ICU Medical, Inc. (NASDAQ ICUI) opened at 189.10 on Wednesday. The firm has a market cap of $3.75 billion, a P/E ratio of 75.73 and a beta of 0.35. ICU Medical, Inc. has a 52 week low of $125.49 and a 52 week high of $189.15. The firm’s 50-day moving average price is $177.38 and its 200 day moving average price is $166.78.
ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.58 by ($0.06). The business had revenue of $331.51 million during the quarter, compared to analysts’ expectations of $318.30 million. ICU Medical had a return on equity of 7.56% and a net margin of 6.10%. The company’s quarterly revenue was up 242.8% on a year-over-year basis. During the same quarter last year, the business posted $1.15 EPS. Equities analysts forecast that ICU Medical, Inc. will post $4.11 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/04/profund-advisors-llc-has-420000-position-in-icu-medical-inc-icui.html.
In other news, Director Robert S. Swinney sold 463 shares of ICU Medical stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $181.25, for a total transaction of $83,918.75. Following the completion of the sale, the director now owns 14,330 shares in the company, valued at approximately $2,597,312.50. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Scott E. Lamb sold 23,772 shares of ICU Medical stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $170.02, for a total value of $4,041,715.44. Following the sale, the chief financial officer now owns 9,050 shares of the company’s stock, valued at approximately $1,538,681. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 213,012 shares of company stock valued at $36,438,659. 15.90% of the stock is owned by company insiders.
A number of equities research analysts have weighed in on the company. Zacks Investment Research raised ICU Medical from a “sell” rating to a “hold” rating in a report on Monday, September 11th. BidaskClub upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday, June 17th. Sidoti cut ICU Medical from a “buy” rating to a “neutral” rating in a report on Tuesday, June 20th. Finally, Gabelli reissued a “buy” rating on shares of ICU Medical in a report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. ICU Medical has an average rating of “Hold” and a consensus price target of $193.00.
About ICU Medical
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI).
Receive News & Stock Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related stocks with our FREE daily email newsletter.